Nurix therapeutics announces $40 million registered direct offering

San francisco, july 08, 2022 (globe newswire) -- nurix therapeutics, inc. (nasdaq: nrix), a clinical-stage biopharmaceutical company developing targeted protein modulation drugs, today announced that it has entered into a securities purchase agreement with two healthcare-focused investment funds to sell, in a registered direct offering, pre-funded warrants to purchase 2,869,440 shares of common stock at a price of $13.939 per pre-funded warrant for total gross proceeds of approximately $40 million, before deducting estimated offering expenses. the offering is expected to close on july 11, 2022, subject to the satisfaction of customary closing conditions.
NRIX Ratings Summary
NRIX Quant Ranking